GSK plc Sponsored ADR (GSK)
GSK reaffirms 2026 guidance after strong first-quarter performance
GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceuticals giant, has reiterated its full-year 2026 guidance after delivering a strong first quarter, with core operating profit growth and earnings per share both expected to rise between 7% and 9% at constant exchange rates. Turnover growth is forecast to be between 3% and 5%, supported by expectations of low double-digit growth in Specialty Medicines, offset by low single-digit declines to stable performance in both Vaccines and General Medicines.
GSK beats quarterly profit estimates on strength in respiratory, general medicines
British drugmaker GSK reported first-quarter profit above analysts' expectations on Wednesday, helped by strong sales of its respiratory and other general medicines.
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought by AnaptysBio, the US biotechnology company, in a dispute over the licence for cancer drug dostarlimab. The Delaware Chancery Court granted TESARO's motion to dismiss AnaptysBio's claim for anticipatory breach, though the ruling does not address the core contractual dispute between the parties.
GSK (GSK) Earnings Expected to Grow: Should You Buy?
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK: 'Strong Buy' On Mo-Rez Oncology Expansion Potential
GSK maintains a 'Strong Buy' rating, driven by robust Oncology portfolio growth and promising pipeline catalysts. The company's BLENREP is regaining traction in multiple myeloma, outperforming JNJ's DARZALEX in OS and potential label expansions to 2nd/1st-line settings. Mo-Rez [B7-H4 ADC] posted impressive phase 1 response rates in endometrial and platinum-resistant ovarian cancers, supporting five global pivotal phase 3 trials in 2026.
GSK sees blockbuster potential in targeted cancer therapy after promising early data
British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in patients with advanced, hard-to-treat cancers.
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK withdrew an application of a drug touted by Trump and RFK Jr. as a potential treatment for autism. The drug's label last month was updated so that generic versions of it can be marketed for a rare genetic, neurological condition, but not autism.
Generic versions of the drug will still be available to treat a rare genetic condition.
GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript
GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript
Broker reiterates GSK 'buy' as court ruling lifts vaccine cloud
Shore Capital has reiterated its buy recommendation on GSK PLC (LSE:GSK, NYSE:GSK) with a fair value of 2,500p, arguing the pharmaceutical group's shares are too cheap given the scale of its growth ambitions and that two of the market's main concerns about the business are beginning to fade. The broker's analyst, Dr Sean Conroy, said GSK, which has a market capitalisation of around £79 billion, trades at 14 times his 2026 earnings estimate and 12 times his 2027 forecast, a level he described as undemanding relative to peers on comparable growth.
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.
